{"id":15672,"date":"2012-10-26T14:30:00","date_gmt":"2012-10-26T12:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/farmaci-il-3010-incontro-stampa-in-senato-su-farmaci-biologici-biosimilari-e-ddl-1875\/"},"modified":"2012-10-26T14:30:00","modified_gmt":"2012-10-26T12:30:00","slug":"farmaci-il-3010-incontro-stampa-in-senato-su-farmaci-biologici-biosimilari-e-ddl-1875","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/farmaci-il-3010-incontro-stampa-in-senato-su-farmaci-biologici-biosimilari-e-ddl-1875\/","title":{"rendered":"Drugs: 10\/30 press meeting in the Senate on biological drugs, biosimilars and DDL 1875"},"content":{"rendered":"<p class=\"MsoNormal\" style=\"text-align: left; line-height: normal; margin: 0cm 0cm 10pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto\"><span style=\"font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; font-size: 12pt\">(AGENPARL) - Rome, Oct. 26 - \u201cBiological drugs and biosimilar drugs: protecting patients, defending patents, promoting innovation, guaranteeing savings. The 1875 bill&quot;. This is the theme of the press meeting organized by Assobiotec, which is part of Federchimica, with the collaboration of the Parliamentary Association for the protection and promotion of the right to prevention. The meeting will take place next Tuesday 30 October from 11.30 in the Nassiriya hall of the Senate of the Republic, Piazza Madama 11, Rome. The 1875 bill represents an essential opportunity to fill a legislative gap in a sector, that of biotechnological drugs \u2013 whether they are innovative or biosimilars \u2013 increasingly important for our country. The meeting aims to provide a contribution to clarity on some critical issues that derive from the improper use of biosimilar drugs, due to the shortcomings of the national regulatory framework. The meeting moderated by the journalist Walter Gatti will be attended by Alessandro Sidoli, President of Assobiotec; Antonio Tomassini, President of the XII Hygiene and Health Commission of the Senate; Cesare Cursi, President of the X Industry, Commerce and Tourism Commission of the Senate; Gianfranco Polillo, Undersecretary of the Ministry of Economy and Finance; Tom Moore, EuropaBio Biosimilars Topic Leader; Luca Pani, Director General of AIFA and Claudio Gustavino, member of the XII Hygiene and Health Commission of the Senate. The participation of Renato Balduzzi, Minister of Health is expected.<\/span><\/p>\n<p class=\"MsoNormal\" style=\"text-align: left; line-height: normal; margin: 0cm 0cm 10pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto\"><span style=\"font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; font-size: 12pt\"><\/p>\n<p><img decoding=\"async\" id=\"rg_hi\" class=\"rg_hi uh_hi\" alt=\"\" data-width=\"232\" data-height=\"94\" style=\"width: 153px; height: 48px\" src=\"https:\/\/encrypted-tbn2.gstatic.com\/images?q=tbn:ANd9GcRm8pM8hbmodqt8eWX7PApAacb5e8fCFsqs0yxmVtH-7EHODzFw\" \/><\/p>\n<p><\/span><\/p>","protected":false},"excerpt":{"rendered":"<p>(AGENPARL) &#8211; Roma, 26 ott &#8211; &ldquo;Farmaci biologici e farmaci biosimilari: tutelare i pazienti, difendere i brevetti, promuovere l&rsquo;innovazione, garantire il risparmio. Il DDL 1875&rdquo;. E&#8217; questo il tema dell&rsquo;incontro stampa organizzato da Assobiotec, che fa parte di Federchimica, con la collaborazione dell&rsquo;Associazione parlamentare per la tutela e la promozione del diritto alla prevenzione. L&rsquo;incontro &hellip;<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-15672","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/15672","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=15672"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/15672\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=15672"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=15672"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=15672"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}